Wells Fargo & Company Lantern Pharma Inc. Transaction History
Wells Fargo & Company
- $468 Billion
- Q2 2025
A detailed history of Wells Fargo & Company transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 4,986 shares of LTRN stock, worth $22,187. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,986
Previous 5,406
7.77%
Holding current value
$22,187
Previous $19,000
21.05%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding LTRN
# of Institutions
35Shares Held
2.22MCall Options Held
16.4KPut Options Held
0-
Bios Capital Management, LP Fort Worth, TX1.08MShares$4.79 Million4.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA364KShares$1.62 Million0.0% of portfolio
-
Cm Management, LLC200KShares$890,0000.65% of portfolio
-
Geode Capital Management, LLC Boston, MA91.9KShares$408,9140.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny90.6KShares$403,1700.0% of portfolio
About Lantern Pharma Inc.
- Ticker LTRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,830,900
- Market Cap $48.2M
- Description
- Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...